Intestinal FXR agonists can promote adipose tissue browning and reduce obesity and insulin resistance, suggesting that FXR activation could be a therapeutic strategy for treating obesity and metabolic syndrome (42). This evidence concerns the gene NR1H4 and metabolic syndrome.